Antipsychotic polypharmacy and risk of death from natural causes in patients with schizophrenia: a population-based nested case-control study.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Journal of Clinical Psychiatry

• Publication date

  2010-01-31

• Fields of study

  Medicine

• Identifiers
  DOI 10.4088/JCP.08m04818yelPMID 19895781
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Immeasurable time bias in observational studies of drug effects on mortality.

  2008cited by this paper
• A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time?

  2007cited by this paper
• Schizophrenia, neuroleptic medication and mortality

  2006cited by this paper
• The Danish Civil Registration System. A cohort of eight million persons.

  2006cited by this paper
• Mortality in schizophrenia

  2006cited by this paper
• Antipsychotic medication dispensing and associated odds ratios of death in elderly veterans and war widows, 2001.

  2006cited by this paper
• The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update.

  2004cited by this paper
• Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000.

  2004cited by this paper
• A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation.

  2004cited by this paper
• The psychiatric comorbidity of epilepsy

  2004cited by this paper
• Polypharmacy in patients with schizophrenia.

  2003cited by this paper
• Urban-rural mental health differences in Great Britain: findings from the National Morbidity Survey

  2003cited by this paper
• Prospective analysis of premature mortality in schizophrenia in relation to health service engagement: a 7.5-year study within an epidemiologically complete, homogeneous population in rural Ireland.

  2003cited by this paper
• Recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorder: implications for state mental health policy.

  2002cited by this paper
• Combination antipsychotics: pros, cons, and questions.

  2002cited by this paper
• Neuroleptics and mortality in schizophrenia: prospective analysis of deaths in a French cohort of schizophrenic patients.

  2002cited by this paper
• Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data.

  2001cited by this paper
• Physical health of people with severe mental illness.

  2001cited by this paper
• Psychoactive substance use diagnoses among psychiatric in‐patients

  2000cited by this paper
• The Danish National Hospital Register. A valuable source of data for modern health sciences.

  1999cited by this paper
• Mortality in schizophrenia

  1998cited by this paper
• Excess mortality of mental disorder

  1998cited by this paper
• Excess mortality of schizophrenia

  1997cited by this paper
• Medical comorbidity in schizophrenia.

  1996cited by this paper
• Mortality and causes of death in schizophrenic patients in Denmark

  1990cited by this paper

• Benzodiazepine use in schizophrenia: A review of the literature

  2025cites this paper
• Medication Exposure and Mortality in Patients With Schizophrenia

  2024cites this paper
• Mortality in patients with schizophrenia in Japan

  2024influential citation
• An Argument for Antipsychotic Polypharmacy.

  2023cites this paper
• Safety of Antipsychotic Polypharmacy Versus Monotherapy in a Nationwide Cohort of 61,889 Patients With Schizophrenia.

  2023cites this paper
• Antipsychotic Polypharmacy-Related Cardiovascular Morbidity and Mortality: A Comprehensive Review

  2022influential citation
• Exposure to psychotropic medications and mortality in schizophrenia: a 5-year national cohort study

  2022cites this paper
• The Cumulative Effect of Antipsychotic Usage on Mortality in Schizophrenia: A Nationwide Population-based Cohort Study in Korea

  2022cites this paper
• Maintenance Therapy of Psychosis Spectrum Disorders in a Real-World Setting: Antipsychotics Prescription Patterns and Long-Term Benzodiazepine Use

  2022cites this paper
• Differences in Antipsychotic Treatment Discontinuation Among Veterans With Schizophrenia in the U.S. Department of Veterans Affairs.

  2021cites this paper
• Comparing psychotropic medication prescribing in personality disorder between general mental health and psychological services: retrospective cohort study

  2021cites this paper
• Antipsychotic Polypharmacy Is Associated With Adverse Drug Events in Psychiatric Inpatients

  2021cites this paper
• Antipsychotic Polypharmacy for the Management of Schizophrenia: Evidence and Recommendations

  2021cites this paper
• Self-Harm Among Forensic Psychiatric Inpatients With Schizophrenia Spectrum Disorders: An Explorative Analysis

  2021cites this paper
• Comparison of the Schein and Osdi Questionnaire as Indicator of Tear Film Stability in Patients with Schizophrenia.

  2021cites this paper
• Antipsychotic polypharmacy in adult patients diagnosed with schizophrenia: A retrospective study

  2021cites this paper
• A nationwide study of the risk of all-cause, sudden death, and cardiovascular mortality among antipsychotic-treated patients with schizophrenia in Taiwan.

  2021cites this paper
• Polypharmacy in schizophrenia.

  2020cites this paper
• Does antipsychotic combination therapy reduce the risk of hospitalization in schizophrenia?

  2020cites this paper
• Tackling myths of common prescribing patterns in schizophrenia amongst Egyptian psychiatrists

  2020cites this paper
• Polytherapy in schizophrenia in light of the literature data

  2020cites this paper
• The association between primary care quality and health-care use, costs and outcomes for people with serious mental illness: a retrospective observational study

  2020cites this paper
• Commentary on Robert Whitaker's viewpoint

  2020cites this paper
• Check the effects: systematic assessment of antipsychotic side-effects in an inpatient cohort

  2020cites this paper
• Opening the curtains for better sleep in psychotic disorders - considerations for improving sleep treatment.

  2020cites this paper
• Antipsychotic polypharmacy in schizophrenia: evolving evidence and rationale

  2020cites this paper
• Mortality risk from long-term treatment with antipsychotic polypharmacy vs monotherapy among adults with serious mental illness: A systematic review and meta-analysis of observational studies.

  2020cites this paper
• Association of Benzodiazepines and Antidepressants With 180-Day Mortality Among Patients With Dementia Receiving Antipsychotic Pharmacotherapy: A Nationwide Registry-Based Study.

  2020cites this paper
• Association of antipsychotics adherence and cardiovascular disease among newly diagnosed schizophrenia patients: A national cohort among Koreans.

  2020cites this paper
• Multiple antipsychotics use in patients with schizophrenia: Why do we use it, what are the results from patient follow-ups?

  2020cites this paper
• Benzodiazepines and antipsychotics in severe mental illness Optimizing and characterizing prescribing practice

  2019cites this paper
• Antipsychotics and risk of natural death in patients with schizophrenia

  2019cites this paper
• Factors That Affect Continuation of Antipsychotic Long-Acting Injections.

  2019cites this paper
• Evaluation du mésusage des benzodiazépines et de ses conséquences chez les patients atteints de pathologies psychiatriques

  2019cites this paper
• Pharmakotherapie und andere somatische Behandlungsverfahren (Modul 4a)

  2019cites this paper
• NDT_A_199748 1863..1871

  2019cites this paper
• Antipsychotic Polypharmacy: A Dirty Little Secret or a Fashion?

  2019cites this paper
• Association of Antipsychotic Polypharmacy vs Monotherapy With Psychiatric Rehospitalization Among Adults With Schizophrenia

  2019cites this paper
• Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology

  2019cites this paper
• Mortality in mental disorders: Are we approaching to close the gap respect to other medical specialties? The case of schizophrenia

  2019cites this paper
• Dying Too Soon: Excess Mortality in Severe Mental Illness

  2019cites this paper
• Association Between Antipsychotic Polypharmacy and Outcomes for People With Serious Mental Illness in England.

  2019cites this paper
• Combination Therapy for Treatment Resistant Schizophrenia

  2019cites this paper
• Long‐term antipsychotic polypharmacy prescribing in secondary mental health care and the risk of mortality

  2018cites this paper
• [Use and misuse of benzodiazepines in patients with psychiatric disorders].

  2018cites this paper
• Use of antipsychotics and benzodiazepines in connection to minimising coercion and mechanical restraint in a general psychiatric ward

  2018cites this paper
• Second-generation antipsychotic drugs and short-term mortality: a systematic review and meta-analysis of placebo-controlled randomised controlled trials.

  2018cites this paper
• Benzodiazepine Use among Patients with Schizophrenia in Korea: Analysis of Database of Health Insurance Review Agency

  2017cites this paper
• Demographic Characteristics, Medication Profile and Treatment Outcome of Patients with Very Early-Onset Schizophrenia in One Hospital

  2017cites this paper
• Long-term antipsychotic polypharmacy prescribing in secondary mental health care : detection, predictors and outcomes

  2017cites this paper
• Mortality and use of psychotropic medication in sleep apnoea patients: a population-wide register-based study.

  2017cites this paper
• Association between polypharmacy and death: A systematic review and meta-analysis.

  2017cites this paper
• Antipsychotic polypharmacy in psychiatric practice: is it really doomed?

  2017cites this paper
• Antipsychotics and mortality in a nationwide cohort of 29,823 patients with schizophrenia.

  2017cites this paper
• Changes in antipsychotics and other psychotropic drugs during a 30-month lifestyle intervention among outpatients with schizophrenia

  2017cites this paper
• [Medication-free hospital records - a measure not based on knowledge].

  2017cites this paper
• Real-World Effectiveness of Antipsychotic Treatments in a Nationwide Cohort of 29 823 Patients With Schizophrenia

  2017cites this paper
• Benzodiazepine use and risk of mortality among patients with schizophrenia: a retrospective longitudinal study.

  2016cites this paper
• Prolonged-release melatonin versus placebo for benzodiazepine discontinuation in patients with schizophrenia or bipolar disorder: A randomised, placebo-controlled, blinded trial

  2016cites this paper
• Real‐world effectiveness of antipsychotics

  2016cites this paper
• Association between the high-dose use of benzodiazepines and rehospitalization in patients with schizophrenia: a 2-year naturalistic study

  2016cites this paper
• Association Between Antipsychotic Treatment and Advanced Diabetes Complications Among Schizophrenia Patients With Type 2 Diabetes Mellitus.

  2016cites this paper
• Benzodiazepine safety: mortality risk or multiple chronic disease comorbidity?

  2016cites this paper
• Safety and tolerability of antipsychotic co-treatment in patients with schizophrenia: results from a systematic review and meta-analysis of randomized controlled trials

  2016cites this paper
• Prescribing patterns in schizophrenic patients attending a tertiary care hospital, Kerala

  2016cites this paper
• Kapitel 6 – Somatische Therapieverfahren

  2016cites this paper
• Behandlung der Schizophrenie

  2016cites this paper
• Cognition, Adherence and Stigma in Schizophrenia. The COAST study

  2015cites this paper
• Cognition, Adherence and Stigma in Schizophrenia

  2015cites this paper
• Psychiatric Disorders and Psychopharmacologic Treatment as Risk Factors in Elective Fast-track Total Hip and Knee Arthroplasty

  2015cites this paper
• Psychotische Störungen – ein kurzer Überblick über die Empfehlungen der aktuellen Behandlungsleitlinien

  2015cites this paper
• 5 – Pharmacologie de la schizophrénie

  2015cites this paper
• Antipsychotic treatment and mortality in schizophrenia.

  2015cites this paper
• The European studies on mortality in schizophrenia.

  2015cites this paper
• Polypharmacy for Obsessive-Compulsive Symptoms in Schizophrenia: Augmentation and Combination Strategies

  2015cites this paper
• Bridging the gap between education and appropriate use of benzodiazepines in psychiatric clinical practice

  2015cites this paper
• Mortality and Cumulative Exposure to Antipsychotics, Antidepressants, and Benzodiazepines in Patients With Schizophrenia: An Observational Follow-Up Study.

  2015cites this paper
• Does antipsychotic drug use increase the risk of long term mortality? A systematic review and meta-analysis of observational studies

  2015cites this paper
• Investigational drugs for anxiety in patients with schizophrenia

  2015cites this paper
• VariationinLong-TermAntipsychotic PolypharmacyandHigh-DosePrescribing AcrossPhysiciansandHospitals

  2014cites this paper
• [Venous thromboembolism as an adverse effect of antipsychotic treatment].

  2014cites this paper
• Risk of arrhythmia induced by psychotropic medications: a proposal for clinical management.

  2014cites this paper
• Post-Stroke Mortality, Stroke Severity, and Preadmission Antipsychotic Medicine Use – A Population-Based Cohort Study

  2014cites this paper
• Critical review of antipsychotic polypharmacy in the treatment of schizophrenia.

  2014cites this paper
• Incidence, predictors, healthcare utilization, and cost associated with antipsychotic polypharmacy in the Texas Medicaid population

  2014cites this paper
• Does a history of suicide attempt predict higher antipsychotic dosage in schizophrenia?

  2014cites this paper
• Increased all-cause mortality with psychotropic medication in Parkinson's disease and controls: a national register-based study.

  2014cites this paper
• Variation in long-term antipsychotic polypharmacy and high-dose prescribing across physicians and hospitals.

  2014cites this paper
• A Survey study of the Satisfaction and attitude of the Korean Psychiatrists toward Antipsychotic Polypharmacy

  2014cites this paper
• Antipsychotic polypharmacy and high-dose prescription in schizophrenia: a 5-year comparison

  2014cites this paper
• Mortality, disability, psychiatric treatment and medication in first-onset schizophrenia in Finland : the register linkage study

  2014cites this paper
• Mortality and Its Determinants in People With Psychotic Disorder

  2013cites this paper
• Antipsychotics and mortality in first-onset schizophrenia: prospective Finnish register study with 5-year follow-up.

  2013cites this paper
• World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: Update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects

  2013cites this paper
• Description of long-term polypharmacy among schizophrenia outpatients

  2013cites this paper
• Sleep and circadian rhythm dysregulation in schizophrenia.

  2013cites this paper
• Polypharmacy in Psychiatry Practice, Volume I

  2013cites this paper
• Metabolic Syndrome and Antipsychotic Polypharmacy

  2013cites this paper
• Antipsychotic Polypharmacy in Schizophrenia: ‘Secret Sauce or Wild Abandon?’

  2013cites this paper
• Schizophrenia, antipsychotics and risk of hip fracture: a population-based analysis.

  2013cites this paper